Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. Summary
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about BIOGEN INC.
10:42aBIOGEN : Stifel Adjusts Biogen's Price Target to $344 from $430, Keeps Buy Rating
MT
10:20aBIOGEN : Cantor Fitzgerald Adjusts Price Target on Biogen to $327 From $427, Maintains Neu..
MT
10/14BIOGEN : Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-..
AQ
10/14BIOGEN : New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes an..
AQ
10/14BIOGEN : New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do..
AQ
10/13BIOGEN : Preliminary Analysis Suggests Certain Multiple Sclerosis Therapies May Reduce COV..
MT
10/13BIOGEN : New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes an..
AQ
10/13Biogen Inc. Announces New Data from its Industry-Leading Portfolio of Multiple Sclerosi..
CI
10/13BIOGEN : New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do..
AQ
10/13BIOGEN : People Treated With MS Therapies Achieve Antibody Response to Covid-19 Vaccinatio..
DJ
10/12BIOGEN : Morgan Stanley Adjusts Biogen PT to $447 from $455, Keeps Overweight Rating
MT
10/08BIOGEN : Jefferies Adjusts Biogen PT to $400 from $500, Keeps Buy Rating
MT
10/08BIOGEN : Barclays Adjusts Biogen's Price Target to $290 from $395, Keeps Equalweight Ratin..
MT
10/06BIOGEN : to Report Third Quarter 2021 Financial Results October 20, 2021
PU
10/06BIOGEN : RBC Trims Price Target on Biogen to $325 From $326, Maintains Sector Perform Rati..
MT
More most relevant news
All news about BIOGEN INC.
10:42aBIOGEN : Stifel Adjusts Biogen's Price Target to $344 from $430, Keeps Buy Rating
MT
10:20aBIOGEN : Cantor Fitzgerald Adjusts Price Target on Biogen to $327 From $427, Maintains Neu..
MT
04:45aAnalysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
01:00aDeals, data buzz could help biotech shares exit Wall St's 'no man's land'
RE
10/14BIOGEN : Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-..
AQ
10/14BIOGEN : New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes an..
AQ
10/14BIOGEN : New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do..
AQ
10/13BIOGEN : Preliminary Analysis Suggests Certain Multiple Sclerosis Therapies May Reduce COV..
MT
10/13BIOGEN : New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes an..
AQ
10/13Biogen Inc. Announces New Data from its Industry-Leading Portfolio of Multiple Sclerosi..
CI
More news
News in other languages on BIOGEN INC.
10/11Alzheimer-Mittel von Morphosys und Roche vor möglicher US-Zulassung
10/08Roche erhält von FDA Therapiedurchbruch-Status für Alzheimer Kandidaten
09/29IMPRESE : Europe's Best Workplaces 21, Italia conta 20 aziende premiate
09/28Eisai, partenaire de Biogen, soumet à la FDA une demande de licence de produit biologiq..
09/21Apple will iPhones zur Erkennung von Depressionen einsetzen - Kreise
09/20Byooviz de Biogen et Samsung Bioepis approuvé par la FDA
09/19ALZHEIMER : un nouvel espoir, timide, pour traiter la maladie
09/19Alzheimer, la démence la plus connue
09/17L'Agence européenne des médicaments recommande la mise sur le marché de Vumerity de Bio..
09/16L'étude de Biogen sur la vixotrigine dans la neuropathie à petites fibres atteint un cr..
More news
Analyst Recommendations on BIOGEN INC.
10:42aBIOGEN : Stifel Adjusts Biogen's Price Target to $344 from $430, Keeps Buy Rating
MT
10:20aBIOGEN : Cantor Fitzgerald Adjusts Price Target on Biogen to $327 From $427, Maintains Neu..
MT
10/12BIOGEN : Morgan Stanley Adjusts Biogen PT to $447 from $455, Keeps Overweight Rating
MT
10/08BIOGEN : Jefferies Adjusts Biogen PT to $400 from $500, Keeps Buy Rating
MT
10/08BIOGEN : Barclays Adjusts Biogen's Price Target to $290 from $395, Keeps Equalweight Ratin..
MT
More recommendations
Press releases
10/14BIOGEN : Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-..
AQ
10/14BIOGEN : New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes an..
AQ
10/14BIOGEN : New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do..
AQ
10/13BIOGEN : New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes an..
AQ
10/13BIOGEN : New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do..
AQ
More press releases
Upcoming event on BIOGEN INC.